JP Morgan Chase’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$770K Hold
30,000
– – ﹤0.01% 4951
2026
Q2
$932K Buy
+30,000
New +$741K ﹤0.01% 4719
2024
Q1
– Sell
-3,000
Closed -$57.3K – 7803
2023
Q4
$57.3K Sell
3,000
-30,200
-91% -$483K ﹤0.01% 5956
2023
Q3
$596K Hold
33,200
– – ﹤0.01% 4379
2023
Q2
$674K Buy
+33,200
New +$632K ﹤0.01% 4316
2022
Q3
– Sell
-3,100
Closed -$79K – 6789
2022
Q2
$79K Hold
3,100
– – ﹤0.01% 5516
2022
Q1
$98K Buy
+3,100
New +$104K ﹤0.01% 5521

Other funds holding RCUS

JP Morgan Chase's RCUS Position: Q3 2026 in Review

JP Morgan Chase increased its Arcus Biosciences (RCUS) stake by 83% in Q3 2026, buying an estimated $9.8M and bringing the position to 765,041 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2233.

JP Morgan Chase first reported a position in RCUS in Q1 2018 and has held it in 35 quarters since. 244 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • JP Morgan Chase held 765,041 shares of Arcus Biosciences worth $19.7M as of Q3 2026.
  • JP Morgan Chase bought 346,798 Arcus Biosciences shares in Q3 2026, an estimated $9.8M.
  • Arcus Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2233 holding.
  • JP Morgan Chase first reported a position in Arcus Biosciences in Q1 2018 and has held it in 35 quarters since.
  • 244 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.